Metformin Hydrochloride Accord (Metformin Hydrochloride)

The drug belongs to the biguanide class and works through several mechanisms: it suppresses hepatic gluconeogenesis, reduces intestinal absorption of glucose, and enhances peripheral insulin sensitivity via activation of AMP‑activated protein kinase, collectively leading to lower blood glucose concentrations.

The appropriate dose is individualized by the prescribing healthcare professional based on factors such as the patient’s renal function, glycemic targets, and response to therapy. Dosage adjustments are made according to clinical judgment and monitoring results.

Safety in pregnancy and lactation should be evaluated by a qualified clinician. Metformin crosses the placenta and is excreted in breast milk; therefore, the potential benefits and risks must be weighed before use in pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, metformin has a lower risk of hypoglycemia and may promote modest weight loss. Unlike insulin, it is administered orally and does not require injection. It is often used as first‑line therapy because of its efficacy, safety profile, and cardiovascular benefits observed in large trials.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability.

Metformin Hydrochloride Accord is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse effect is lactic acidosis, a rare but potentially fatal condition that can occur in patients with significant renal impairment, hepatic disease, or excessive alcohol intake. Prompt medical attention is required if symptoms such as unexplained fatigue, muscle pain, or rapid breathing develop.

Metformin is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those who are currently experiencing severe infection or dehydration. Clinicians should assess each patient’s medical history before initiating therapy.